Rocky Mountain Cancer Centers

Sorting 1 by

Accepting patients

AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Learn more
  • Monoclonal Antibody
  • CD47
  • Closed Label (Masked)
  • Placebo
  • Randomization
  • Phase 2